Pulmonary Fibrosis Therapeutics
1. Esbriet patent expiration
Treatment: Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; D...
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420674 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7696326 | LEGACY PHARMA | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
Dec, 2027
(1 year, 11 months from now) | |
| US9561217 | LEGACY PHARMA | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(3 years ago) | |
| US7696236 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7988994 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8013002 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US8778947 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Aug, 2033
(7 years from now) | |
| US7767225 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US7767700 | LEGACY PHARMA | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(1 year, 11 months from now) | |
| US7816383 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US8754109 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US8318780 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US7910610 | LEGACY PHARMA | Methods of administering pirfenidone therapy |
Jan, 2030
(4 years from now) | |
| US7566729 | LEGACY PHARMA | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8383150 | LEGACY PHARMA | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(2 years from now) | |
| US8084475 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US8592462 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8753679 | LEGACY PHARMA | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(8 months from now) | |
| US8609701 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US8648098 | LEGACY PHARMA | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(4 years from now) | |
| US7635707 | LEGACY PHARMA | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(3 years from now) | |
| US10188637 | LEGACY PHARMA | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 15 October, 2014
Dosage: TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
2. Ofev patent expiration
Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with s...
OFEV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(1 year, 10 months ago) | |
| US6762180 | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Oct, 2025
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7989474 | BOEHRINGER INGELHEIM | Use of Lck inhibitors for treatment of immunologic diseases |
Apr, 2024
(1 year, 9 months ago) | |
| US10154990 | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jan, 2026
(16 hours ago) | |
| US9907756 | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Jun, 2029
(3 years from now) | |
| US10105323 | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Jun, 2029
(3 years from now) | |
|
US6762180 (Pediatric) | BOEHRINGER INGELHEIM | Substituted indolines which inhibit receptor tyrosine kinases |
Apr, 2026
(2 months from now) | |
|
US9907756 (Pediatric) | BOEHRINGER INGELHEIM | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Dec, 2029
(3 years from now) | |
|
US10105323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical dosage form for immediate release of an indolinone derivative |
Dec, 2029
(3 years from now) | |
|
US10154990 (Pediatric) | BOEHRINGER INGELHEIM | Medicaments for the treatment or prevention of fibrotic diseases |
Jul, 2026
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents